Tech Company Financing Transactions
Borealis Biosciences Funding Round
Novartis, Versant Ventures and private investors participated in a $150 million Series A venture round for Borealis Biosciences. The round closed on 8/20/2024.
Transaction Overview
Company Name
Announced On
8/20/2024
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series A
Investors
Novartis (Lead Investor)
Versant Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Undisclosed
Vancouver, BC, Undisclosed
Canada
Vancouver, BC, Undisclosed
Canada
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jerel Davis
Browse more venture capital transactions:
Prev: 8/20/2024: Orderly Network venture capital transaction
Next: 8/20/2024: Resal venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs